Latest & greatest articles for copd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd

141. Prognostic assessment in COPD without lung function: the B-AE-D indices (PubMed)

Prognostic assessment in COPD without lung function: the B-AE-D indices Several composite markers have been proposed for risk assessment in chronic obstructive pulmonary disease (COPD). However, choice of parameters and score complexity restrict clinical applicability. Our aim was to provide and validate a simplified COPD risk index independent of lung function.The PROMISE study (n=530) was used to develop a novel prognostic index. Index performance was assessed regarding 2-year COPD-related (...) mortality and all-cause mortality. External validity was tested in stable and exacerbated COPD patients in the ProCOLD, COCOMICS and COMIC cohorts (total n=2988).Using a mixed clinical and statistical approach, body mass index (B), severe acute exacerbations of COPD frequency (AE), modified Medical Research Council dyspnoea severity (D) and copeptin (C) were identified as the most suitable simplified marker combination. 0, 1 or 2 points were assigned to each parameter and totalled to B-AE-D or B-AE-D-C

Full Text available with Trip Pro

2016 EvidenceUpdates

142. The inflammasome pathway in stable COPD and acute exacerbations (PubMed)

The inflammasome pathway in stable COPD and acute exacerbations Chronic obstructive pulmonary disease (COPD) is characterised by pulmonary and systemic inflammation that bursts during exacerbations of the disease (ECOPD). The NLRP3 inflammasome is a key regulatory molecule of the inflammatory response. Its role in COPD is unclear. We investigated the NLRP3 inflammasome status in: 1) lung tissue samples from 38 patients with stable COPD, 15 smokers with normal spirometry and 14 never-smokers (...) ; and 2) sputum and plasma samples from 56 ECOPD patients, of whom 41 could be reassessed at clinical recovery. We observed that: 1) in lung tissue samples of stable COPD patients, NLRP3 and interleukin (IL)-1β mRNA were upregulated, but both caspase-1 and ASC were mostly in inactive form, and 2) during infectious ECOPD, caspase-1, oligomeric ASC and associated cytokines (IL-1β, IL-18) were significantly increased in sputum compared with clinical recovery. The NLRP3 inflammasome is primed

Full Text available with Trip Pro

2016 ERJ open research

143. Only severe COPD is associated with being underweight: results from a population survey (PubMed)

Only severe COPD is associated with being underweight: results from a population survey Low body mass index (BMI) and malnutrition in chronic obstructive pulmonary disease (COPD) are associated with a poor prognosis. The prevalence of underweight, as well as overweight, in severity grades of COPD is sparsely investigated in studies of the general population and the associated patterns of risk factors are not well established. The aim of the present study was to determine the association between (...) severity grades of airflow limitation in COPD, and both underweight and obesity when corrected for possible confounding factors. The study is based on pooled data from the OLIN (Obstructive Lung Disease in Northern Sweden) studies. Complete records with lung function, BMI and structured interview data were available from 3942 subjects (50.7% women and 49.3% men). COPD and severity grading were defined using the Global Initiative for Chronic Obstructive Lung Disease criteria. In sensitivity analyses

Full Text available with Trip Pro

2016 ERJ open research

144. Inflammatory bowel disease and risk of mortality in COPD (PubMed)

Inflammatory bowel disease and risk of mortality in COPD Patients with chronic obstructive pulmonary disease (COPD) have higher incidence and prevalence of other chronic inflammatory diseases, including inflammatory bowel disease (IBD). We assessed whether IBD onset increases mortality risk in patients with COPD or asthma-associated COPD.Two population-based cohorts of COPD and asthma-COPD subjects were identified using the administrative health databases in Québec, Canada, 1990-2007. Death (...) records were retrieved from the death certificate registry. Cox proportional hazards models were used to assess the impact of newly developed IBD on mortality risk.The COPD and asthma-COPD cohorts included 273 208 and 26 575 patients, respectively, of which 697 and 119 developed IBD. IBD increased the risk of all-cause mortality in both COPD (hazard ratio 1.23, 95% CI 1.09-1.4) and asthma-COPD (hazard ratio 1.65, 95% CI 1.23-2.22). In asthma-COPD patients, IBD increased the risk of mortality from

Full Text available with Trip Pro

2016 EvidenceUpdates

145. Functional characterisation of bone marrow-derived mesenchymal stromal cells from COPD patients (PubMed)

Functional characterisation of bone marrow-derived mesenchymal stromal cells from COPD patients Autologous bone marrow-derived mesenchymal stromal cells (BM-MSCs) are evaluated for clinical use in chronic obstructive pulmonary disease (COPD) patients, but it is unclear whether COPD affects BM-MSCs. To investigate this, BM-MSCs from nine COPD patients and nine non-COPD age-matched controls were compared with regard to immunophenotype, growth and differentiation potential, and migration capacity (...) . Other functional assays included the response to pro-inflammatory stimuli and inducers of the nuclear factor (erythroid derived 2)-like 2 antioxidant response element (Nrf2-ARE) pathway, and effects on NCI-H292 airway epithelial cells. No significant differences were observed in terms of morphology, proliferation and migration, except for increased adipocyte differentiation potential in the COPD group. Both groups were comparable regarding mRNA expression of growth factors and inflammatory mediators

Full Text available with Trip Pro

2016 ERJ open research

146. Tai Chi for chronic obstructive pulmonary disease (COPD). (PubMed)

Tai Chi for chronic obstructive pulmonary disease (COPD). Tai Chi, a systematic callisthenic exercise first developed in ancient China, involves a series of slow and rhythmic circular motions. It emphasises use of 'mind' or concentration to control breathing and circular body motions to facilitate flow of internal energy (i.e. 'qi') within the body. Normal flow of 'qi' is believed to be essential to sustain body homeostasis, ultimately leading to longevity. The effect of Tai Chi on balance (...) and muscle strength in the elderly population has been reported; however, the effect of Tai Chi on dyspnoea, exercise capacity, pulmonary function and psychosocial status among people with chronic obstructive pulmonary disease (COPD) remains unclear.• To explore the effectiveness of Tai Chi in reducing dyspnoea and improving exercise capacity in people with COPD.• To determine the influence of Tai Chi on physiological and psychosocial functions among people with COPD.We searched the Cochrane Airways

Full Text available with Trip Pro

2016 Cochrane

147. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. (PubMed)

Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. Most guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice treatment for patients with chronic obstructive pulmonary disease (COPD) who have a high risk of exacerbations. The role of treatment with a LABA-LAMA regimen in these patients is unclear.We conducted a 52-week, randomized, double-blind, double-dummy, noninferiority (...) trial. Patients who had COPD with a history of at least one exacerbation during the previous year were randomly assigned to receive, by inhalation, either the LABA indacaterol (110 μg) plus the LAMA glycopyrronium (50 μg) once daily or the LABA salmeterol (50 μg) plus the inhaled glucocorticoid fluticasone (500 μg) twice daily. The primary outcome was the annual rate of all COPD exacerbations.A total of 1680 patients were assigned to the indacaterol-glycopyrronium group, and 1682 to the salmeterol

Full Text available with Trip Pro

2016 NEJM

148. Another Choice for Prevention of COPD Exacerbations. (PubMed)

Another Choice for Prevention of COPD Exacerbations. 27181835 2016 06 21 2018 12 02 1533-4406 374 23 2016 Jun 09 The New England journal of medicine N. Engl. J. Med. Another Choice for Prevention of COPD Exacerbations. 2284-6 10.1056/NEJMe1604444 Donohue James F JF From the Division of Pulmonary Diseases and Critical Care Medicine, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill. eng Editorial Comment 2016 05 15 United States N Engl J Med 0255562 0028-4793 0

2016 NEJM

149. Smoking, Not COPD, as the Disease. (PubMed)

Smoking, Not COPD, as the Disease. 27168438 2016 05 16 2018 12 02 1533-4406 374 19 2016 May 12 The New England journal of medicine N. Engl. J. Med. Smoking, Not COPD, as the Disease. 1885-6 10.1056/NEJMe1515508 Fabbri Leonardo M LM From Dipartimento di Medicina Metabolica, Nuovo Ospedale Civile Sant'Agostino Estense, Azienda Unitá Sanitaria Locale di Modena, Azienda Ospedaliero-Universitaria Policlinico di Modena, Università degli Studi di Modena e Reggio Emilia, Modena, Italy. eng Editorial

2016 NEJM

150. Increasing burden of COPD in rural India: an example why India warrants primary healthcare reforms (PubMed)

Increasing burden of COPD in rural India: an example why India warrants primary healthcare reforms Battle against COPD: time to reinforce the primary healthcare units of rural areas of India to combat lung diseases http://ow.ly/ZAwge.

Full Text available with Trip Pro

2016 ERJ open research

151. Measurement duration impacts variability but not impedance measured by the forced oscillation technique in healthy, asthma and COPD subjects (PubMed)

Measurement duration impacts variability but not impedance measured by the forced oscillation technique in healthy, asthma and COPD subjects The forced oscillation technique (FOT) is gaining clinical acceptance, facilitated by more commercial devices and clinical data. However, the effects of variations in testing protocols used in FOT data acquisition are unknown. We describe the effect of duration of data acquisition on FOT results in subjects with asthma, chronic obstructive pulmonary (...) disease (COPD) and healthy controls. FOT data were acquired from 20 healthy, 22 asthmatic and 18 COPD subjects for 60 s in triplicate. The first 16, 30 and 60 s of each measurement were analysed to obtain total, inspiratory and expiratory resistance of respiratory system (Rrs) and respiratory system reactance (Xrs) at 5 and 19 Hz. With increasing duration, there was a decrease in total and expiratory Rrs for healthy controls, total and inspiratory Rrs for asthmatic subjects and magnitude of total

Full Text available with Trip Pro

2016 ERJ open research

152. Home health monitoring compared with usual care for patients with moderate to severe COPD

Home health monitoring compared with usual care for patients with moderate to severe COPD evidence note In response to an enquiry from Quality and Efficiency Support Team, Scottish Government Number 60 March 2016 What is the clinical effectiveness, cost effectiveness and safety of home health monitoring compared with usual care for patients with moderate to severe chronic obstructive pulmonary disease? What is an evidence note Evidence notes are rapid reviews of published secondary clinical (...) it is not possible to draw firm conclusions regarding the clinical effectiveness of home health monitoring (HHM) for patients with moderate to severe chronic obstructive pulmonary disease (COPD). ? Based on the evidence reviewed, there was no statistically significant difference in mortality rates between patients receiving HHM interventions (HHM alone and HHM plus usual care) and those receiving usual care. ? In studies variously comparing HHM plus usual care with usual care, and HHM alone with usual care

2016 Evidence Notes from Healthcare Improvement Scotland

153. Home health monitoring compared with usual care for patients with moderate to severe COPD

Home health monitoring compared with usual care for patients with moderate to severe COPD File name: 2016-003 AS COPD v1.0.doc Version: 1.0 Date: 21 March 2016 Produced by: SHTG Page: 1 Review date: March 2018 Advice Statement 003/2016 March 2016 What is the clinical effectiveness, cost effectiveness, safety and patient satisfaction of home health monitoring compared with usual care for patients with moderate to severe chronic obstructive pulmonary disease? This advice has been produced (...) following completion of evidence note 60 by Healthcare Improvement Scotland, in response to an enquiry from the Quality and Efficiency Support Team Background In 2012/2013, practice team information data estimated that about 20 women and 18 men per 1,000 patients, across all ages, consulted a general practitioner or practice nurse at least once due to chronic obstructive pulmonary disease (COPD). The Scottish Government’s national telehealth and telecare delivery plan includes an objective to expand

2016 SHTG Advice Statements

154. Economic surveillance for chronic obstructive pulmonary disease (COPD) in Alberta

Economic surveillance for chronic obstructive pulmonary disease (COPD) in Alberta application/octet-stream

2016 Institute of Health Economics

155. Physical activity assessed in routine care predicts mortality after a COPD hospitalisation (PubMed)

Physical activity assessed in routine care predicts mortality after a COPD hospitalisation The independent relationship between physical inactivity and risk of death after an index chronic obstructive pulmonary disease (COPD) hospitalisation is unknown. We conducted a retrospective cohort study in a large integrated healthcare system. Patients were included if they were hospitalised for COPD between January 1, 2011 and December 31, 2011. All-cause mortality in the 12 months after discharge (...)  years), there were 464 (20%) deaths. Patients who were insufficiently active or active had a 28% (adjusted HR 0.72 (95% CI 0.54-0.97), p=0.03) and 47% (adjusted HR 0.53 (95% CI 0.34-0.84), p<0.01) lower risk of death, respectively, in the 12 months following an index COPD hospitalisation compared to inactive patients. Any level of MVPA is associated with lower risk of all-cause mortality after a COPD hospitalisation. Routine assessment of physical activity in clinical care would identify persons

Full Text available with Trip Pro

2016 ERJ open research

156. Understanding variation in length of hospital stay for COPD exacerbation: European COPD audit (PubMed)

Understanding variation in length of hospital stay for COPD exacerbation: European COPD audit Chronic obstructive pulmonary disease (COPD) care across Europe has high heterogeneity with respect to cost and the services available. Variations in length of stay (LOS) may be attributed to patient characteristics, resource and organisational characteristics, and/or the so-called hospital cluster effect. The European COPD Audit in 13 countries included data from 16 018 hospitalised patients

Full Text available with Trip Pro

2016 ERJ open research

157. Global Strategy for Diagnosis, Management, and Prevention of COPD

Global Strategy for Diagnosis, Management, and Prevention of COPD Global Strategy for Diagnosis, Management, and Prevention of COPD - 2016 - Global Initiative for Chronic Obstructive Lung Disease - GOLD Global Strategy for Diagnosis, Management, and Prevention of COPD – 2016 [/vc_column_text][/vc_column][vc_column column_padding=”no-extra-padding” column_padding_position=”all” background_color_opacity=”1″ background_hover_color_opacity=”1″ width=”1/6″][/vc_column][/vc_row][vc_row type (...) ″][vc_column_text] Please reference this document as follows: From the Global Strategy for the Diagnosis, Management and Prevention of COPD , Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2016. Available from: https://goldcopd.org/. GOLD documents are protected by copyright. A single copy of this document may be downloaded for your own educational use, but copies may not be made for distribution or posted on a website without authorization from GOLD. Click here to by the GOLD Science Committee

2016 European Respiratory Society

158. Validation of the DECAF score to predict hospital mortality in acute exacerbations of COPD (PubMed)

Validation of the DECAF score to predict hospital mortality in acute exacerbations of COPD Hospitalisation due to acute exacerbations of COPD (AECOPD) is common, and subsequent mortality high. The DECAF score was derived for accurate prediction of mortality and risk stratification to inform patient care. We aimed to validate the DECAF score, internally and externally, and to compare its performance to other predictive tools.The study took place in the two hospitals within the derivation study

Full Text available with Trip Pro

2016 EvidenceUpdates

159. Randomised controlled trial: LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients

Randomised controlled trial: LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients Article Text

2016 Evidence-Based Medicine (Requires free registration)

160. Cohort study: A higher overall diet quality is inversely associated with the risk of chronic obstructive pulmonary disease (COPD) in men and women

Cohort study: A higher overall diet quality is inversely associated with the risk of chronic obstructive pulmonary disease (COPD) in men and women A higher overall diet quality is inversely associated with the risk of chronic obstructive pulmonary disease (COPD) in men and women | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use (...) (COPD) in men and women Article Text Aetiology/Harm Cohort study A higher overall diet quality is inversely associated with the risk of chronic obstructive pulmonary disease (COPD) in men and women Rania A Mekary Statistics from Altmetric.com Commentary on : Varraso R , Chiuve SE , Fung TT , et al . Alternate Healthy Eating Index 2010 and risk of chronic obstructive pulmonary disease among US women and men: prospective study . Request Permissions If you wish to reuse any or all of this article

2016 Evidence-Based Medicine (Requires free registration)